TrialPK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
Trial details
- Registry ID
- NCT05380635
- Phase
- Phase 2
SNGX
Soligenix
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
5Trials in this database
10Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell LymphomaNCT05380635 | Soligenix | Phase 2 | Completed | 2022-08-16Actual |
| Topical SGX302 for Mild-to-Moderate PsoriasisNCT05442190 | Soligenix | Phase 2 | Completed | 2025-10-22Actual |
| HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCLNCT06149247 | Soligenix | Phase 2 | Completed | 2024-05-31Actual |
| Dusquetide for the Treatment of Behcet's DiseaseNCT06386744 | Soligenix | Phase 2 | Completed | 2025-05-23Actual |
| Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCLNCT06470451 | Soligenix | Phase 3 | Terminated | 2026-05-22Actual |
Topical SGX302 for Mild-to-Moderate Psoriasis
Trial details
- Registry ID
- NCT05442190
- Phase
- Phase 2
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Trial details
- Registry ID
- NCT06149247
- Phase
- Phase 2
Dusquetide for the Treatment of Behcet's Disease
Trial details
- Registry ID
- NCT06386744
- Phase
- Phase 2
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
Trial details
- Registry ID
- NCT06470451
- Phase
- Phase 3
Latest recorded trial changes
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
NCT06470451 · Soligenix
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
80 participants (planned)
+ After
70 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Jul 2026
+ After
22 May 2026
Recruitment status changed
− Before
Recruiting
+ After
Terminated
Topical SGX302 for Mild-to-Moderate Psoriasis
NCT05442190 · Soligenix
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
47 participants (planned)
+ After
15 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Oct 2025
+ After
22 Oct 2025
Recruitment status changed
− Before
Recruiting
+ After
Completed